All In Biotech

BLA 761112 · Ablynx Nv

Cablivi

Caplacizumab-Yhdp · Injection

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Feb 6, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

9

4 Phase 3, 0 recruiting

FAERS reports

1,784

749 serious, 109 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2026.

CABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. ( 1 )

Mechanism: Caplacizumab-yhdp targets the A1-domain of vWF, and inhibits the interaction between vWF and platelets, thereby reducing both vWF-mediated platelet adhesion and platelet consumption.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 2025 Supplement 18 · Efficacy · priority review OrphanLabelLetter
  • Feb 6, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • CABLIVI · CAPLACIZUMAB-YHDP 11MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Caplacizumab" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication619
  • off label use208
  • adamts13 activity decreased161
  • epistaxis133
  • platelet count decreased133
  • fatigue111
  • contusion89
  • thrombotic thrombocytopenic purpura84
  • headache83
  • injection site pain82
  • condition aggravated80
  • adamts13 activity abnormal73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2019132
2020194
2021240
2022269
2023256
2024236
2025270
2026187

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cablivi (Caplacizumab-Yhdp)

2024 spending

$24.6M

Beneficiaries

50

113 claims

Per beneficiary

$491,222

$8,151.71 per unit

View as table
YearSpending
2020$13,383,596
2021$12,714,119
2022$17,437,325
2023$20,162,189
2024$24,561,101

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Ablynx Nv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.